IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Ongoing Investigation of Eagle Pharmaceuticals Inc. and Advises Investors with Losses to Contact the Firm

LOS ANGELES--()--Lundin Law PC announces it is investigating claims against Eagle Pharmaceuticals Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) concerning possible violations of federal securities laws. The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.

“We have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2.”

To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus the Company making misrepresentations about the FDA approval process for its new anticoagulant drug, KANGIO™. On February 25, 2016, the Company’s CEO stated, regarding the pending New Drug Application for KANGIO™, "We have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2." When the truth was revealed, shares dropped, causing investors harm

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com

Lundin Law PC